C
Cellerant Therapeutics
Cell and antibody immunotherapies for hematologic malignancies
About Cellerant Therapeutics
Cellerant Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2003 and headquartered in San Carlos, California. The company focuses on developing cell- and antibody-based immunotherapies to treat hematologic malignancies and other blood-related disorders.
The former President and CEO, Ram Mandalam, Ph.D., has over thirty years of experience in cell therapy and biologics development. Before leading Cellerant, he was the Executive Director of Product Development at Geron Corporation and held research and development roles at Aastrom Biosciences. Under his leadership, Cellerant established a pipeline of therapeutic candidates and advanced from an early-stage to a clinical-stage company. The company has raised a total of $51 million over 15 funding rounds from investors including Allen & Company and SBIR.
Cellerant's product portfolio is based on regulating the hematopoietic (blood-forming) system. One of its primary products is romyelocel-L (CLT-008), a universal, off-the-shelf myeloid progenitor cell therapy designed to reduce infection risk during neutropenia, a common side effect of chemotherapy. A key advantage of romyelocel-L is that it does not require HLA matching between donor and recipient. In a Phase 2 clinical trial for patients with Acute Myeloid Leukemia (AML), romyelocel-L demonstrated a reduction in infections and hospital stay duration. The FDA has granted it Regenerative Medicine Advanced Therapy (RMAT) designation. The therapy was also developed for Acute Radiation Syndrome (ARS) under a contract with the Biomedical Advanced Research and Development Authority (BARDA).
The company is also advancing two antibody-drug conjugate (ADC) products. CLT030 is an ADC that targets the CLL1 protein, which is highly expressed on AML leukemic stem cells (LSCs) but not on normal hematopoietic stem cells. This specificity allows CLT030 to selectively kill cancer cells and LSCs, which are often responsible for disease relapse, while sparing healthy cells. A second ADC, CSC012-ADC, is in development for other hematologic malignancies and solid tumor indications. In 2020, Cantargia AB acquired a patent portfolio from Cellerant related to the IL1RAP protein, a target for antibody therapy in leukemia.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Sep 2016 | $1.5M | — | Undisclosed | — |
| DEBTDebt | Apr 2016 | $2M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Cellerant Therapeutics is 50 monthly website visits, down 50% over the last three months. Cellerant Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cellerant Therapeutics in the San Carlos ecosystem
The Cellerant Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Allen & Company
MPM BioImpact
Novel Bioventures- CGCX Venture Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cellerant Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellerant Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







